With a revenue increase of 6.24% in the second quarter 2026, year on year to cumulative value of $746 million, Pacira Biosciences Inc 's revenue per employee grew on a trailing twelve months basis to $ 900,077. The productivity of Pacira Biosciences Inc 's employees was 0.0%, above the company average. Within the Healthcare sector Employees of 90 other companies have achieved higher revenue per employee. While Pacira Biosciences Inc 's total ranking has deteriorated compared to the previous quarter from 652 to 963. Pacira Biosciences Inc has 829 employees.
TAMPA, Fla. Sept. 09, 2024 - Pacira BioSciences, Inc. a leading player dedicated to non-opioid pain management and regenerative health solutions, recently announced the provision of inducement awards to 17 new employees on September 4, 2024. These awards were granted under Pacira s Amended and Restated 2014 Inducement Plan with the intention of enticing these employees to join the company. The Compensation Committee of the Board of Directors duly approved these awards in compliance with Nasdaq Listing Rule 5635(c)(4). Simultaneously, Pacira BioSciences Inc s stock has witnessed a commendable gain of 7.96% over the past five trading days. Moreover, the company s revenue per employee has displayed promising growth over the trailing twelve months, accumulating to an impressive $545,883. Specifically, the second quarter of 2024 experienced a 11.03% YoY revenue increase, reaching a cumulative value of $679 million, marking an all-time high for the company.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
